Genmab A/S (NASDAQ:GMAB) Rating Lowered to Hold at Wall Street Zen

Genmab A/S (NASDAQ:GMAB) was downgraded by equities research analysts at Wall Street Zen from a “buy” rating to a “hold” rating in a research note issued to investors on Saturday.

GMAB has been the subject of several other reports. Zacks Research cut shares of Genmab A/S from a “strong-buy” rating to a “hold” rating in a report on Friday, October 31st. Guggenheim raised shares of Genmab A/S from a “neutral” rating to a “buy” rating and set a $43.00 price target for the company in a research report on Tuesday, September 23rd. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Genmab A/S in a research report on Wednesday, October 8th. HC Wainwright reiterated a “buy” rating on shares of Genmab A/S in a research note on Monday, October 27th. Finally, Johnson Rice restated a “buy” rating on shares of Genmab A/S in a research note on Monday, October 27th. One investment analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $39.50.

Genmab A/S Stock Performance

Shares of Genmab A/S stock traded down $0.18 during midday trading on Friday, hitting $28.66. The company had a trading volume of 2,026,734 shares, compared to its average volume of 2,648,188. Genmab A/S has a 52-week low of $17.24 and a 52-week high of $33.65. The stock has a market capitalization of $18.40 billion, a P/E ratio of 12.20, a P/E/G ratio of 1.57 and a beta of 0.96. The company has a 50 day moving average of $29.61 and a 200 day moving average of $24.43.

Genmab A/S (NASDAQ:GMAB) last released its earnings results on Thursday, August 7th. The company reported $0.54 EPS for the quarter, topping analysts’ consensus estimates of $0.39 by $0.15. The firm had revenue of $925.00 million for the quarter, compared to analysts’ expectations of $5.77 billion. Genmab A/S had a return on equity of 24.48% and a net margin of 41.36%. Equities research analysts forecast that Genmab A/S will post 1.45 EPS for the current year.

Institutional Investors Weigh In On Genmab A/S

Large investors have recently made changes to their positions in the company. Cromwell Holdings LLC boosted its holdings in shares of Genmab A/S by 136.3% in the third quarter. Cromwell Holdings LLC now owns 1,531 shares of the company’s stock worth $47,000 after buying an additional 883 shares during the last quarter. Headlands Technologies LLC raised its position in Genmab A/S by 1,525.0% in the first quarter. Headlands Technologies LLC now owns 1,560 shares of the company’s stock worth $31,000 after acquiring an additional 1,464 shares during the period. Osaic Holdings Inc. boosted its stake in shares of Genmab A/S by 37.8% during the 2nd quarter. Osaic Holdings Inc. now owns 1,603 shares of the company’s stock worth $33,000 after acquiring an additional 440 shares during the last quarter. CWM LLC grew its position in shares of Genmab A/S by 50.5% during the 2nd quarter. CWM LLC now owns 1,797 shares of the company’s stock valued at $37,000 after acquiring an additional 603 shares during the period. Finally, Caitong International Asset Management Co. Ltd grew its position in shares of Genmab A/S by 124.3% during the 1st quarter. Caitong International Asset Management Co. Ltd now owns 1,931 shares of the company’s stock valued at $38,000 after acquiring an additional 1,070 shares during the period. 7.07% of the stock is currently owned by institutional investors.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.